export const personas = [
  {
    id: 1,
    name: 'Vangelis Vergetis, PhD',
    title: 'CEO and board member',
    filters: [
      { position: 'all', order: 12 },
      { position: 'board', order: 6 },
      { position: 'executive', order: 1 },
    ],
    img: 'assets/images/Vangelis_Vergetis.jpg',
    linkedin: 'https://www.linkedin.com/in/vangelisvergetis',
    bio: `
      <p>
        Vangelis has been working in the intersection 
        of healthcare, technology, and data science 
        for more than 15 years.
      </p>
      <p>
        He started his career as a consultant at McKinsey and at Hakluyt,
        where he spent twelve years advising biopharmaceutical executives 
        on several topics - particularly in launching drugs across 
        disease areas, and in designing and implementing
        their commercial models and infrastructure. 
      </p>
      <p>
        Immediately prior to Epikast, Vangelis was the 
        co-founder and CEO of Intelligencia, a software 
        company that utilizes AI to assess and reduce 
        the risk of clinical trials. He currently serves 
        as a board advisor to the company.
      </p>
      <p>
        He previously served as a founding board member and member of the executive committee 
        at the Alliance for AI in Healthcare (AAIH), 
        and as member of the advisory board for 
        Cornell's Bowers College of Computing & 
        Information Science (CIS).
      </p>
      <p>
        Vangelis holds a 
        PhD in Electrical Engineering from the University 
        of Pennsylvania, and a BS in 
        Computer Science from Cornell University.
      </p>
    `,
  },
  {
    id: 2,
    name: 'Stelios Papadopoulos, PhD',
    title: 'Chairman of the board',
    filters: [
      { position: 'all', order: 8 },
      { position: 'board', order: 1 },
    ],
    img: 'assets/images/Stelios_papadopoulos.jpg',
    linkedin: null,
    bio: `
      <p>
        Stelios brings more than four decades of experience in the 
        biopharmaceutical industry in various roles: as a company founder, 
        executive, investment banker, and leader in the global healthcare 
        sector.
      </p>
      <p>
        Stelios is Chairman of the Board of Directors of Biogen, Inc., 
        Exelixis, Inc., and Regulus Therapeutics, Inc. He is a co-founder 
        of Exelixis, as well as co-founder and former Chairman of Anadys 
        Pharmaceuticals (acquired by Hoffman–La Roche in 2011) and 
        Cellzome (acquired by GlaxoSmithKline in 2012). In 
        the not-for-profit sector, Stelios is a member of the 
        Board of Visitors of Duke Medicine, a member of the Global 
        Advisory Board of the Duke Institute for Health Innovation, 
        and co-founder and Chairman of Fondation Santé 
        (<a href="https://www.fondationsante.org">www.fondationsante.org</a>), a foundation providing 
        research support and mentorship to biomedical 
        scientists in Greece and Cyprus.
      </p>
      <p>
        Stelios spent six years (2000-06) at Cowen & Co., LLC, most 
        recently as Vice Chairman, where as an investment banker he 
        focused on the biotech and pharma sectors. Prior to joining 
        Cowen, he spent 13 years as an investment banker at PaineWebber, 
        Incorporated where he was most recently Chairman of 
        PaineWebber Development Corp., a PaineWebber subsidiary 
        focusing on biotechnology. He joined PaineWebber in 1987 
        from Drexel Burnham Lambert where he was an analyst in 
        the Equity Research Department covering the biotechnology industry. 
        Prior to Drexel, he was the biotechnology analyst of Donaldson, 
        Lufkin & Jenrette. Stelios has received multiple honors and 
        awards for his work in the biopharma industry as a company 
        founder, adviser, and financier.
      </p>
      <p>
        Before coming to Wall Street, Stelios was on the faculty of the 
        Department of Cell Biology at New York University School of 
        Medicine. Stelios holds an MS in physics, a PhD in biophysics, 
        and an MBA in finance, all from New York University.
      </p>
    `,
  },
  {
    id: 3,
    name: 'Daphne Karydas',
    title: 'Board member',
    filters: [
      { position: 'all', order: 4 },
      { position: 'board', order: 3 },
    ],
    img: 'assets/images/Daphne.jpg',
    linkedin: 'https://www.linkedin.com/in/daphne-karydas-493b17/',
    bio: `
      <p>
        Daphne has over 25 years of experience in 
        financial and operations leadership roles 
        focused in the biopharmaceutical industry, 
        where she has brought an interdisciplinary 
        approach to implementing growth strategies 
        for biopharmaceutical and asset 
        management companies.
      </p>
      <p>
        She is currently the President, COO, and CFO of Flare 
        Therapeutics, which she joined in October 2021. 
        Prior to Flare she was the CFO of Syndax 
        Pharmaceuticals, and also served as SVP of 
        Strategy and Corporate Financial Planning & 
        Analysis at Allergan plc, where she oversaw 
        the company’s long-term financial and 
        business strategy until its acquisition 
        by Abbvie in May 2020. She joined 
        Allergan in April 2017 as the SVP of 
        Global Investor Relations and Strategy, 
        leading engagement with the investment 
        community and business strategy development.
      </p>
      <p>
        Prior to her senior operating roles in the industry, 
        Daphne served as Executive Director and Senior 
        Healthcare Analyst at J.P. Morgan Asset Management. 
        Previously, she was a Portfolio Manager and Senior 
        Healthcare Analyst at The Boston Company Asset 
        Management, a BNY Mellon company. Earlier in 
        her career she was a VP at Goldman Sachs Asset 
        Management focused on healthcare, as well as a 
        member of Goldman Sachs’ healthcare investment 
        banking team. Before joining Goldman Sachs she 
        was a Project Chemical Engineer at Merck, 
        where she focused on process development 
        for novel vaccines.
      </p>
      <p>
        Daphne received a BA and MS in chemical engineering 
        from MIT and an MBA from Harvard Business School.
      </p>
    `,
  },
  {
    id: 4,
    name: 'Dimitri Papalexopoulos',
    title: 'Board member',
    filters: [
      { position: 'all', order: 9 },
      { position: 'board', order: 5 },
    ],
    img: 'assets/images/Dimitris_Papalexopoulos.jpg',
    linkedin: null,
    bio: `
      <p>
        Dimitri is Chairman of Titan Cement Group, a cement 
        and building materials producer active since 1902. 
        The group directly employs about 5,500 people, 
        operates cement plants in 10 countries, and is 
        active in many more. Prior to joining Titan in 1989, 
        Dimirti started his career as a business consultant 
        for McKinsey & Company in the USA and Germany.
      </p>
      <p>
        He is Chairman of the Board of the Hellenic Federation 
        of Enterprises (SEV), Vice-Chairman of the European 
        Round Table for Industry (ERT) and chairs the ERT’s 
        Energy Transition & Climate Change Committee. 
        He is a member of the Board of the Foundation for 
        Economic and Industrial Research (IOBE), the 
        Hellenic Foundation for European and Foreign Policy 
        (ELIAMEP), and of Endeavor Greece.
      </p>
      <p>
        Dimitri holds a M.Sc. 
        in Electrical Engineering from the Swiss Federal 
        Institute of Technology (ETHZ) and an MBA 
        from Harvard Business School.
      </p>
    `,
  },
  {
    id: 5,
    name: 'Mike Krzan',
    title: 'Advisor',
    filters: [
      { position: 'all', order: 5 },
      { position: 'advisors', order: 1 },
    ],
    img: 'assets/images/Mike_Krzan.jpg',
    linkedin: 'https://www.linkedin.com/in/mike-krzan',
    bio: `
      <p>
        Mike brings a lifetime of experience in building and 
        running high-performing patient services organizations, 
        having spent more than 20 years in the space. He led 
        Biogen’s patient services center in North Carolina 
        for more than a decade, and prior to that was a SVP 
        for member services and pharmacy operations at Medco. 
      </p>
      <p>
        While at Biogen, Mike was a member of the US Senior 
        Leadership Team, developed and set the direction for 
        the patient services organization to support $8B of 
        revenue, launched seven products (including a blockbuster 
        drug and an orphan drug), and collaborated with 
        field sales leaders to identify trends, define 
        tactics for improved performance, and ensure national 
        team alignment. 
      </p>
      <p>
        He holds a BS in Pharmacy 
        from Duquesne University.
      </p>
    `,
  },
  {
    id: 6,
    name: 'Angelos Kapsimanis',
    title: 'Chief Technology Officer',
    filters: [
      { position: 'all', order: 3 },
      { position: 'executive', order: 3 },
    ],
    img: 'assets/images/Angelos.png',
    linkedin: 'https://www.linkedin.com/in/angeloskapsimanis',
    bio: `
      <p>
        Angelos has been working in the tech industry for more than two decades, 
        with experience across 65+ countries. He has led teams across multiple 
        verticals and industries, with a focus on data, machine learning, and AI.
      </p>
      <p>
        He has spent a significant amount of his career in the FinTech industry, 
        helping Klarna to expand globally and reach a valuation of $70B. 
        While at Klarna he managed teams interspersed across the planet, 
        focusing on analytics, machine learning, real-time decision making, 
        and risk management. Prior to Klarna, Angelos built the whole technology 
        function for Motionlogic, an analytics company that is part of the Deutsche 
        Telekom group, and helped it achieve a 52-fold increase in revenues in 3 years. 
        He bootstrapped and successful led to exit Aton Solar, which developed embedded 
        systems and telemetry solution for solar energy facilities.
      </p>
      <p>
        He holds an MS in Machine Learning from Georgia Tech, a second Masters 
        in Computational Statistics from De Montfort University in the UK, and a 
        BS in Industrial Informatics in the University of Applied Sciences in Kavala, Greece.
      </p>
    `,
  },
  {
    id: 7,
    name: 'Oleg Nodelman',
    title: 'Board member',
    filters: [
      { position: 'all', order: 7 },
      { position: 'board', order: 4 },
    ],
    img: 'assets/images/Oleg.png',
    linkedin: 'https://www.linkedin.com/in/oleg-nodelman-375131',
    bio: `
      <p>
        Oleg is the founder and Portfolio Manager of EcoR1 Capital LLC, 
        a biotech-focused investment fund established in 2013, 
        which invests in companies at all stages of research and 
        development. With nearly twenty years of experience in 
        biotech investing, he has expertise in all aspects of 
        investment management and deep roots in the biotech 
        and scientific communities. 
      </p>
      <p>
        Before founding EcoR1, Oleg was a portfolio manager at BVF 
        Partners, one of the first hedge funds dedicated to the 
        biotechnology sector. In addition to Epikast, he currently serves as a Board 
        Member for Prothena Biosciences (NASDAQ: PRTA), AnaptysBio 
        (Nasdaq: ANAB), Nuvation Bio (Nasdaq: NUVB), Panacea 
        (Nasdaq: PANA), Scorpion Therapeutics, Aktis Oncology, 
        ReCode, and Paratus. 
      </p>
      <p>
        Oleg holds a BS in Foreign Service with a concentration in 
        Science and Technology from Georgetown University.
      </p>
    `,
  },
  {
    id: 8,
    name: 'Amit Singhal, PhD',
    title: 'Advisor',
    filters: [
      { position: 'all', order: 11 },
      { position: 'advisors', order: 3 },
    ],
    img: 'assets/images/Amit.jpg',
    linkedin: 'https://www.linkedin.com/in/amit-singhal-09723574/',
    bio: `
      <p>
        Amit is known as the man behind Google Search, having led the 
        Google Search team for over 15 years - from its early days 
        in 2000 until his departure in 2016. He has received several 
        awards and distinctions, including being named a Google Fellow, 
        elected to the National Academy of Engineering, elected Fellow 
        of the ACM (Association for Computing Machinery), and 
        called one of the "smartest people in tech" by Fortune magazine.
      </p>
      <p>
        He is currently dedicated to giving back to his community 
        through the Sitare Foundation (<a href="https://www.sitare.org">www.sitare.org</a>), a non-profit 
        organization that he co-founded together with his wife, Shilpa. 
        Sitare is focusing on providing access to high quality education 
        to the most talented underprivileged children in India. Amit is 
        also an active angel investor and an advisor to 
        technology companies globally.
      </p>
      <p>
        He holds a Bachelor of Engineering degree from IIT Roorkee, 
        an MS from the University of Minnesota Duluth, and a PhD from 
        Cornell University, all in Computer Science and Information Retrieval.
      </p>
    `,
  },
  {
    id: 9,
    name: 'Nassos Zarkalis',
    title: 'Advisor',
    filters: [
      { position: 'all', order: 13 },
      { position: 'advisors', order: 4 },
    ],
    img: 'assets/images/Nassos_Zarkalis.jpg',
    linkedin: null,
    bio: `
      <p>
        Nassos brings 30 years of experience in building and running 
        customer-facing organizations, with a passion for delighted 
        customers, operational excellence, and smart capital allocation. 
      </p>
      <p>
        Until recently, and for more than ten years, he served as Chairman
        and CEO of Wind Hellas, a leading telecoms player in Greece. 
        Working with US-based private equity partners, he led a radical 
        business transformation that resulted in remarkable value creation 
        upon the company's acquisition by BC Partners-owned United Group in 2022. 
        Repositioning the company on a platform of low-cost but high-performing 
        customer acquisition and retention was core to this journey.
      </p>
      <p>
        Prior to Wind, Nassos was CEO of Hellas on Line (HoL), a Greek fixed 
        line telecoms player; again a case of rapid business turnaround on the 
        basis of operational excellence and smart investing. He has also held 
        various commercial roles with Vodafone in Greece and abroad. Before his 
        career in telecommunications, he worked for leading FMCG companies, 
        including P&G and PepsiCo, in sales and marketing roles.
      </p>
      <p>
        Nassos holds a BS in Chemical Engineering from the National Technical 
        University of Athens (NTUA), an MS in Chemical Engineering from the University 
        of Delaware, and an MBA from Henley Business School.
      </p>
    `,
  },
  {
    id: 10,
    name: 'Todd Holmes',
    title: 'Board member',
    filters: [
      { position: 'all', order: 2 },
      { position: 'board', order: 2 },
    ],
    img: 'assets/images/Todd_Holmes.jpg',
    linkedin: 'https://www.linkedin.com/in/todd-holmes-467511/',
    bio: `
      <p>
        Todd is the Founder and Managing Partner of NewVale Capital LLC, 
        a growth equity fund focused on investing in life science services companies. 
        With nearly 20 years of Life Science investing, company-building, and 
        transaction experience across private and public sectors, Todd’s passion is 
        finding solutions to the many complex challenges that face the pharmaceutical industry. 
      </p>
      <p>
        Before founding NewVale, Todd led pharma and pharma services investing at CRG LP, 
        a Healthcare-dedicated structured capital firm. Prior to CRG, he held senior 
        investment roles with Gurnet Point Capital and Third Rock Ventures, helping to 
        build and grow Life Science companies across both development and commercial stages. 
        Earlier in his career, he was an investor with BVF Partners, a biotechnology-focused 
        hedge fund. Todd has been actively involved on numerous industry leadership councils, 
        including the BIO Investment Advisory Board and New England Venture Network.
      </p>
      <p>
        Todd holds a BS in economics from Colgate University, and an MBA from the Wharton School 
        at the University of Pennsylvania.
      </p>
    `,
  },
  {
    id: 11,
    name: 'Brad Prosek',
    title: 'Advisor',
    filters: [
      { position: 'all', order: 10 },
      { position: 'advisors', order: 2 },
    ],
    img: 'assets/images/Brad.jpg',
    linkedin: 'https://www.linkedin.com/in/brad-prosek-66b08b1/',
    bio: `
      <p>
        Brad has been in the biotechnology / life sciences business for over 25 years. He is currently 
        an Operating Partner at EcoR1 Capital LLC. Most recently, he served as SVP and Chief Business Officer 
        at Constellation Pharmaceuticals, an oncology-focused biotech company, from September 2017 until 
        the company was acquired by MorphoSys AG in July 2021. During his tenure, Brad led Corporate 
        Development and Strategy efforts, including Business Development, Commercial Strategy, and Program 
        Leadership. He contributed to multiple financings and overall company operational oversight as a 
        member of Constellation’s executive team. 
      </p>
      <p>
        Prior to joining Constellation, Brad founded and served as President of All Terrain 
        bioPartners LLC, a business development consulting firm. While running All Terrain bioPartners, 
        he advised and provided interim general management services to a global set of life sciences 
        companies. Before that, Brad spent 10 years building Cubist Pharmaceuticals, Inc., a leading 
        biopharmaceutical company in the hospital anti-infectives and products space, from early in its 
        commercialization of its flagship product CUBICIN (daptomycin) through the company’s acquisition 
        by Merck. Prior to Cubist, Brad worked in the US and Europe in commercial operations and business 
        development roles at Biogen and helped to build one of the earliest market access consulting firms 
        to support life sciences companies. He has also served as an advisor to Xenex Disinfection, a 
        medical device company, as well as international relations education-focused nonprofits.  
      </p>
      <p>
        Brad holds an MBA from Columbia University and a BS in Foreign Service from Georgetown
        University, with a concentration in Science & Technology in International Relations.
      </p>
    `,
  },
  {
    id: 12,
    name: 'Yiannis Livanos',
    title: 'Chief Patient & Physician Engagement Officer',
    filters: [
      { position: 'all', order: 6 },
      { position: 'executive', order: 4 },
    ],
    img: 'assets/images/Yiannis_Livanos.jpg',
    linkedin: 'https://www.linkedin.com/in/yannislivanos/',
    bio: `
      <p>
        Yiannis serves as Epikast’s Chief Patient & Physician Engagement Officer, responsible for overseeing 
        all operations related to supporting and engaging with patients, physicians, and other healthcare 
        providers. In this role, he leads our broader team that delivers exceptional experiences. He focuses 
        on innovation and the use of the latest technologies, driving continuous improvement and agility, and enhancing 
        efficiency in the company’s growing operations. 
      </p>
      <p>
        Before joining Epikast, Yiannis spent 16 years in the telecommunications sector, holding commercial 
        roles of increasing responsibility at WIND and NOVA, two leading telecoms companies in Greece. He 
        played a pivotal role in establishing, managing, and growing commercial and customer support 
        operations, and he also led the innovation and set-up of an omnichannel approach to customer 
        engagement, which resulted in improved customer satisfaction and increased revenues.  
      </p>
      <p>
        Yiannis’ extensive experience across operations and his expert grasp of digital technologies have 
        enabled him to lead large, successful businesses with a holistic approach to serving clients. He is 
        committed to ensuring that Epikast's operations are always at the forefront of innovation in the 
        healthcare industry.
      </p>
      <p>
        He holds an MS in Business Innovation & Technology from Athens Information Technology (AIT), and a BS 
        in Business Administration from the University of Essex.
      </p>
    `,
  },
  {
    id: 13,
    name: 'Tina Beamon, JD',
    title: 'Chief Legal & Compliance Officer',
    filters: [
      { position: 'all', order: 1 },
      { position: 'executive', order: 2 },
    ],
    img: 'assets/images/Tina_Beamon.png',
    linkedin: 'https://www.linkedin.com/in/tina-clark-beamon-99144710/',
    bio: `
      <p>
        Tina is an attorney 
        with over 20 years of experience advising the healthcare and pharmaceutical industries. She has deep 
        legal and compliance expertise in the pharmaceutical space, with therapeutic area experience across 
        specialty care, rare diseases, and primary care, and has proudly provided legal and compliance leadership  
        and support across nine new product/new indication launches. 
      </p>
      <p>
        Tina served as the lead attorney for the oncology division and the consumer healthcare division at 
        Boehringer Ingelheim USA Corporation. She was also appointed Counsel and Secretary for the BICARES 
        Foundation, which operated the Patient Assistance Program for US patients, the Product Donation 
        Program, and managed all charitable giving by the organization. Tina also served as Executive Director 
        of Compliance and Ethics at Alexion Pharmaceuticals, with global responsibility for the development of 
        a compliance program supporting R&D, Medical Affairs, Manufacturing Operations, and Business Development 
        functions. She served as the compliance lead supporting Alexion’s global patient support programs. 
      </p>
      <p>
        Most recently, Tina served as Chief Compliance Officer for MEI Pharma, a pre-commercial pharmaceutical company 
        in the oncology therapeutic area. She led the design and implementation of their early-stage compliance 
        program as well as provided critical leadership and governance support for the organization. Tina began 
        her career as a health law associate at Wiggin & Dana, LLP, and a health law and litigation associate at 
        Neubert Pepe and Monteith, PC. She is a Connecticut native and was located in the New Haven office of both firms.
      </p>
      <p>
        Committed to giving back, Tina serves on the Dean’s Advisory Board-College of Liberal Arts and Sciences and the 
        African American Alumni Council for the University of Connecticut. She also served on the Board of Directors for 
        many community-based organizations including CT CASA (Court Appointed Special Advocates) and the Lawyer’s 
        Collaborative for Diversity. She was recognized in 2022 as part of SAVOY Magazine’s Power 300: Most Influential 
        Black Executives in Corporate America. 
      </p>
      <p>
        Tina received her a BS in psychology from the University of Connecticut (magna cum laude, Phi 
        Beta Kappa), and her JD from Washington and Lee University School of Law.  
      </p>
    `,
  },
];
